Two types of TA catheters are currently available: manual and mechanical TA catheters. Previous studies showed that mechanical TA catheter use was related to significantly higher mortality rate compared with patients not treated Abstract-The role of manual thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI) for acute ST-segment-elevation myocardial infarction has been a matter of intense research and debate now. The commonly used manual TA devices in clinical practice are Export AP (Medtronic), Eliminate (Terumo, Japan), Fetch 2 (Bayer Healthcare, the Netherlands), ZEEK (Zeon Medical, Japan), Diver CE (Invatec, Italy), QuickCat (Spectranetics), and Pronto (Vascular solutions, MN). Technical details on these devices are summarized in Table 2 . All these devices are formed on a similar principle, and there is no study yet suggesting convincing clinical advantages of one particular device compared with the other.
T heoretical considerations and initial practical evidence during primary percutaneous coronary intervention (PPCI) indicated that manual thrombus aspiration (TA) might be an effective procedure for reducing distal embolization and improving microvascular perfusion in ST-segment-elevation myocardial infarction (STEMI), especially in patients with high thrombus burden. [1] [2] [3] [4] [5] [6] [7] Results from the single-center TAPAS trial (Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Myocardial Infarction Study) revealed that routine TA improves the primary outcome of microvascular perfusion 1 and showed a significant reduction in long-term mortality during the 1-year follow-up. 2 However, this generally positive view of TA has recently been challenged by the results of 2 major randomized multicenter trials, TASTE (Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia) and TOTAL (Trial of Routine Aspiration Thrombectomy With PCI Versus PCI Alone in Patients With STEMI), which did not show beneficial effects of routine TA use during PPCI. [8] [9] [10] [11] [12] [13] [14] [15] [16] Moreover, the TOTAL study demonstrated that routine TA during percutaneous coronary intervention (PCI) for patients with STEMI was even related to an increased risk of stroke during 1-year follow-up. 10, 17, 18 These findings thus provided evidence for nonbeneficial effects of TA, opposite to what was found from previous studies. 7, 19 Because of the abovementioned controversial results, recommendations for routine TA have been incrementally downgraded from class IIa to III in the most recent clinical guidelines (Table 1) . [20] [21] [22] Despite the class III recommendation for routine TA use before balloon angioplasty or stenting, 21, 22 manual TA might still remain a useful strategy for the interventional cardiologist when treating selected patients with significant thrombus burden during PPCI. 6, 23 Until now, it remains unknown whether TA would still be beneficial when applied only in patients with STEMI with significant thrombus burden. In this review, we present an overview on common instruments used in TA, positive and negative clinical effects of TA during PPCI, and analyze the potential reasons for observed effects, in an effort to guide clinical decision making by physicians for using TA in individual patients with STEMI during PPCI.
The single-center TAPAS trial enrolled 1071 patients with STEMI, showing a trend for a decrease in major adverse cardiac events (MACE) and also indicating a borderline survival benefit in patients with STEMI randomized to the TA group compared with patients in the conventional PCI group at 30 days (mortality: 2.1% [ 12) . The rates of death and MACE at 30 days were both significantly related to myocardial blush grade (MBG), resolution of ST-segment elevation, and ST-segment deviation (P=0.003 for the association between death and MBG), respectively. One-year follow-up of the TAPAS study further revealed that TA before stenting of the infarcted artery significantly improved the clinical outcome compared with conventional PCI alone (Tables 3 and 4) . 
Meta-Analysis Evidence Indicating TA Is Related to Lower Incidence of Death and MACE
In a meta-analysis including 25 clinical trials with 5534 patients (Table 3) , Kumbhani et al 6 concluded that manual TA, but not mechanical TA, was associated with significantly decreased MACE, all-cause mortality, recurrent myocardial infarction (MI), and TVR during 6-to 12-month follow-up in comparison with conventional PPCI alone.
Evidence Indicating TA Can Prevent Microvascular Obstruction and Improve Thrombolysis in MI Flow Grade
The single-center EXPIRA trial (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) evaluated the impact of manual TA on (Table 3) . At 3 months, a reduction in final IS was detected in the TA group (IS mass from 17±15 g to 11±8.7 g; P=0.004; IS% from 14±12% to 9±4.5%; P=0.001), whereas no changes were observed in the conventional PCI group. At 9 months, the rate of MBG ≥2 and the rate of ST-segment resolution >70% were higher in the TA group (88% versus 60% and 64% versus 39%, respectively; P=0.001). 31 Moreover, patients in the TA group had a lower incidence of cardiac mortality (0% versus 4.6%, log-rank P=0.02) than in the conventional PCI group. 31 Above data thus demonstrated that TA can prevent thrombus embolization and preserve microvascular integrity and reduce IS.
Evidence Indicating TA Can Improve Thrombolysis in MI Flow Grade
Gao et al 32 found that patients in the TA group had better Thrombolysis in Myocardial Infarction (TIMI) flow grade classifications and lower incidence of no/slow reflow and MACE compared with conventional PCI alone. Additionally, the MACE rate was also lower in the TA group during the 6-month follow-up. A potential mechanism might be reduced platelet activation, which was suggested by Sahin et al 33 when using TA in patients with STEMI during PPCI. Accordingly, Härle et al 34 reported a heterogeneous use of TA in patients with STEMI between interventionalists and hospitals. Although there was no impact of TA on TIMI 3 patency or mortality after PPCI, a positive impact when using individualized TA on restoration of normal blood flow in the subgroup of STEMI patients with TIMI 0 flow before PPCI was described.
Evidence Indicating That TA Can Attenuate Left Ventricular Remodeling and Decreases the Occurrence of Post-MI Angina
Zia et al 35 reported that TA during primary PCI is associated with reduced myocardial edema, myocardial hemorrhage, left ventricular (LV) remodeling, and incidence of microvascular obstruction after STEMI. Moreover, De Luca et al 36 observed that although cumulative MACE was similar between the conventional PCI and TA groups (10.5% versus 8.6%), TA application was associated with significantly attenuated LV remodeling at 6 months. Lee et al 37 also reported that TA on top of drug-eluting stent implantation decreased the occurrence of post-MI angina at 1 year after acute MI (13.0% versus 22.0%; P=0.04), decreased long-term health costs, and increased post-MI quality of life.
Evidence Suggesting That TA Is Associated With Safe and More Efficient PCI Procedures
Liu et al 38 reported that TA combined with intracoronary tirofiban during recovery from acute MI was effective and relatively well tolerated. Moreover, Geng et al 23 found that TA and intracoronary tirofiban use in patients with STEMI with a large angiographic thrombus burden was safe and effective and did not increase the rate of bleeding complications or MACE.
Fernández-Rodríguez et al 39 showed that the use of TA is linked with a more efficient procedure, in terms of a reduced number of stents per lesion, shorter stent lengths and larger stent sizes. In detail, prevalence of angiographic success was higher (78.8% versus 68%; P=0.015) and final TIMI flow was better (TIMI flow 3: 85.9% versus 78.3%; P=0.04) in the TA group than in the PCI-only group. In addition, the rate of direct stenting was higher (58 
Clinical Trials Not Showing Beneficial
Effects of TA During PPCI Despite above-mentioned clinical evidence supporting the use of TA during PPCI, it is to note that also numerous clinical trials failed to demonstrate beneficial effects of routine TA application during PPCI. These data discussed in detail below are summarized in Table 3 . 48) , and New York Heart Association class IV heart failure (2.1% versus 1.9%; HR, 1.10; 95% CI, 0.83-1.45; P=0.50) were also similar between the 2 groups. 10 Moreover, there was no difference in cardiovascular mortality between the 2 groups at 30 days of follow-up (2.3% in the TA group versus 2.8% in the PCI-alone group; HR, 0.83; 95% CI, 0.65-1.06; P=0.13), within 180 days (3.1% versus 3.5%; HR, 0.90; 95% CI, 0.73-1.12; P=0.34), and after 1 year (3.6% versus 3.8%; HR, 0.93; 95% CI, 0.76-1.14; P=0.48). 10, 16 Even though real-world data might indeed differ from results found in controlled clinical trials, Hachinohe et al 44 also found no significant differences in the 12-month MACE rates (cardiac death, repeat revascularization, and stent thrombosis) between TA and PCI only based on data from the Korea acute MI registry. More recently, Sirker et al 24 analyzed data from a large national STEMI registry cohort (n=98 176 patients) and demonstrated no significant mortality difference between the TA group (n=38 948 patients) and non-TA group (n=59 288 patients), at both 30 days and after 1 year. Subgroup analyses even presented a significantly higher mortality in the mechanical TA group than in the non-TA group at 1-year follow-up.
Evidence Suggesting That TA Does Not Improve Post-PCI TIMI Flow Grade and Microvascular Perfusion
Hoole et al 45 evaluated serial measurements of the index of microcirculatory resistance in patients with STEMI undergoing PPCI and assessed the impact of TA on microvascular function. Their results demonstrated that TA does not seem to be superior to balloon dilatation in maintaining microcirculatory integrity for patients with STEMI, and patients with STEMI with less microcirculatory dysfunction may be even more susceptible to acute iatrogenic microcirculatory injury from TA.
Recently, Sharma et al 17 reported substudy results of the TOTAL trial indicating that routine TA during PCI did not result in improved post-PCI TIMI flow grade or microvascular perfusion (measured by MBG) when compared with PCI alone. Aghlmandi et al 46 
Evidence Indicating That TA Does Not Improve Myocardial Reperfusion Area
The TROFI trial (Randomized Study to Assess the Effect of Thrombus Aspiration on Flow Area in STEMI Patients) was a randomized optical frequency domain imaging study to assess the effect of TA on coronary flow area in patients with STEMI. 47 The primary end point was minimum flow area postprocedure assessed by optical frequency domain imaging, defined as (stent area+incomplete stent apposition area)−(intraluminal defect+tissue prolapsed area). Baseline demographics, preprocedural quantitative coronary angiography, and procedural characteristics were well matched between the TA and PCI-only groups. On optical frequency domain imaging, the stent area (TA group, 7.62±2.23 mm 2 versus PCI-only group, 7.05±2.12 mm 2 ; P=0.14) and minimum flow area (TA group, 7.08±2.14 mm 2 versus PCI-only group, 6.51±1.99 mm 2 ; P=0.12) were similar between both groups. The amount of protrusion, intraluminal defect, and incomplete stent apposition area were also similar between the 2 groups. Above data thus suggest that TA did not affect flow area and stent area. Moreover, TROFI trial data also showed no differences between the TA and PCI-only group for cardiac death, reinfarction in the territory of the infarction-related vessel, allcause death, stroke, definite stent thrombosis, or non-TVR. 47, 48 In the INFUSE-acute MI randomized trial, Stone et al 49 randomized 452 patients with STEMI from 6 countries with large anterior infarcts receiving PPCI plus bivalirudin anticoagulation to treatment with or without a bolus (0.25 mg/kg) of abciximab delivered via intracoronary catheter infusion at the site of the lesion. Patients were also randomized to treatment with or without manual aspiration thrombectomy (TA). As a result of the 2 by 2 randomization, some patients received both treatments, some received neither treatment, and some received one or the other. Cardiac magnetic resonance imaging results showed a significant reduction in IS (% of total LV mass, 15 
Meta-Analyses Indicating That TA Does Not Reduce All-Cause Mortality or MACE and Might Increase the Risk of Stroke
A meta-analysis of 26 randomized controlled trials including 11 780 patients (5869 randomized manual TA patients and 5911 PCI-alone patients; Table 4 ) 27 revealed that there was no statistically significant reduction in the incidences of mortality, reinfarction, or TVR between the 2 groups during the 12-to 24-months follow-up. In another meta-analysis, including 73 research articles (20 trials including 21 660 patients), El Dib et al 30 reported that TA is associated with a potential minor decrease in mortality, but there is a trend for an increase in stroke rate (overall mortality rate [20 28 respectively, also demonstrated that routine TA did not significantly reduce the risk of all-cause mortality, MACE, or stent thrombosis when compared with conventional PCI. In addition, here again TA was shown to be associated with a potentially increased risk of stroke.
Reasons Potentially Responsible for the Divergent Results of TA During PPCI
Multiple factors might be attributable to the divergent effects of TA observed during PCI, including insufficient technical TA because of inexperience of the interventionalist. Several other possible reasons that might be related to the divergent effects of TA among various clinical studies are listed below:
Difference in Study Sample Size
It is to note that some smaller clinical trials, such as the TAPAS trial (n=1071) and EXPIRA trial (n=175) had surrogate end points, and these trials were not powered for mortality outcome. Therefore, data from these small clinical trials should not be used for any direct comparison with large clinical trials, such as TOTAL (n=10 732) and TASTE (n=7244) 
Differences in Patient Collective
The studies cited in this review are certainly heterogeneous because of differences in inclusion and exclusion criteria and clinical end point selection and evaluation of patients. As shown in Table 3 , the enrolled patients were predominantly elderly in previous studies, suggesting that these patients may have had more additional risk factors, which may also affect the outcome of the TA. Presently, there is only limited data of TA outcomes in young patients with STEMI.
Primary End Point Definition Factors
It is to note that the differences on the prespecified primary end point definition and pertinent power calculation from the reported randomized controlled trials might likely affect the major/secondary/tertiary clinical outcomes; cautions are thus needed when interpreting the final results of the various clinical trials.
Timing and Delay of Reperfusion
One of the most important mechanisms which might partly explain limited benefit of TA could be delayed reperfusion. Here, TA might be not that effective for myocardial salvage compared with the scenario of timely performed TA, so that negative effects outweigh potential positive effects.
Thrombus Burden
Initial thrombus burden, before TA, may be the most important determinant of outcome post-TA and stenting. However, initial thrombus burden was not reported in all studies. [50] [51] [52] Actual minor thrombus burden in the treated vessel observed by optical coherence tomography has been reported in a substudy of TOTAL, potentially leading to a significant bias when evaluating the effects of TA compared with other trials.
14 TA has been shown basically useless in case of treating small-sized embolic debris, thrombus, and atherosclerotic plaques. 53, 54 It has to be noted that even though theoretical considerations first of all imply that the net benefit of TA might be greater in cases with larger thrombus burden, this might in fact not be true. That is, negative humoral effects might be even more pronounced in cases with particularly large thrombus masses.
TA Device-Related Factors
Theoretical considerations suggest that not only the efficacy of TA may vary with different aspiration catheters but also the rate of potential complications, such as target-vessel dissection or stroke by thrombus displacement. Frobert et al 25 reported that the efficacy of TA is similar between various device types. In contrast, Tamhane et al 55 demonstrated that the clinical benefits of TA and risk of stroke could in fact be influenced by the device type in use. Particularly when directly comparing the results from different trials, the use of different TA catheters might be an important factor. Moreover, it would be conceivable that improvements in either the technique or the equipment, and application of TA with particular caution, could prove useful to circumvent abovementioned risks, including stroke.
Procedure-Related Factors
In 1 study, it was reported that effective thrombus retrieval was achieved in most cases, and there were few procedural failures. 56 However, particularly the first studies actually did not address the technical difficulties of manual TA and TArelated complications. 2, 16, 19 Despite this report, the varying efficacy post-TA might still be affected by the procedural related factors, and this point needs to be kept in mind when interpreting the study results of TA.
Target-Vessel-Related Factors
The left anterior descending supplies blood to the anterior wall of the heart and the septum, typically supplying 45% to 55% of the LV. The left anterior descending is, therefore, considered the most critical vessel in terms of myocardial blood supply. However, additional factors, such as right ventricular involvement or rhythm disorders, might come into account. Therefore, the clinical benefits of TA may vary with regard to the coronary artery treated. Currently, data focusing on the effects of TA on target vessel are scant.
Interactions With Medication
Medication applied by the treating physicians before, during, or after the procedure might largely impact outcome and complications of PPCI. As 1 example, glycoprotein IIb/IIIa inhibitors were widely used in PPCI at the time of the large initial TA trials and might have significantly improved the prognosis of patients with STEMI. 57 Although this comedication was used regularly in some studies together with TA, 10 it was completely absent in other TA studies.
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Impact and Related Mechanisms of TA on Platelet Activation and Coagulation
Although the hypothesis of thrombus removal by aspiration is appealing, mechanistic data on thrombus composition or its effect on platelet activation or coagulation are limited. It has been reported that in patients with TA, a higher platelet count is observed with increasing mean platelet volume after TA. 33 Although this does not provide direct evidence of platelet activation, it indicates a faster release of more immature platelets from the bone marrow, which in turn would be associated with increased platelet activation. On the contrary, morphological analysis of retrieved thrombi indicates that the major part of the thrombus is fibrin, followed by erythrocytes. More interestingly, there seems to be a correlation of fibrin content and time to thrombectomy, as well as admission hs-TnT. 59 Because of the fact that glycoprotein IIb/IIIa antagonists primarily work by competing with platelet-bound fibrinogen for its RGD-binding site on platelet glycoprotein IIb/IIIa, they are effective in preventing new platelet thrombi. However, they will not interact with fibrin generated by the coagulation cascade. This might indicate that antithrombotic pathways may be more important in subacute MI with visual thrombus Thrombus Aspiration for STEMI than considered previously. Therefore, theoretical assumptions suggest considering the amount of heparine or bivalirudin administered highly important when looking at negative TA trials. In particular, it might be interesting to see whether negative TA trials used more bivalirudin, which has the pharmacological ability to tackle fibrin-bound thrombin as well. However, in cases where coagulation has already occurred and larger amounts of fibrin have been generated, acute antithrombotic treatment will have only a limited effect by stopping further coagulation but not by reducing thrombus burden. These considerations make manual TA a still promising approach whenever visible thrombus is present but not as a routine procedure in all MIs.
Knowing the importance of fibrin generation and thrombin's central role in it, this might also explain the beneficial effects of adding modern anticoagulants, such as rivaroxaban, to dual antiplatelet treatment as investigated in the ATLAS-ACS 2 TIMI 51 trial (Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis in Myocardial Infarction 51), 60 because such an approach positively affects both thrombin-dependent fibrin deposition and platelet activation (Figure 1 ). Adding an anticoagulant not only modulates coagulation and fibrin deposition but indirectly influences leukocyte-dependent tissue factor generation and platelet activation. 61 Tissue factor-expressing cells activate small amounts of factor X (FX) on cell surfaces resulting in thrombin generation. FXa is only active on the cell surface where it is protected from its inactivation through tissue factor pathway inhibitor and antithrombin. Thereafter, thrombin (IIa) unfolds its various effects, predominantly platelet activation by thrombin and conversion of fibrinogen to fibrin. Thus, direct FXa inhibitors should be capable to block the action of FXa on tissue factorbearing cells and platelets, respectively, leading to reduced platelet activation through inhibition of thrombin generation.
The thrombin receptors PAR (protease-activated receptor) 1 and 4, which are present on human platelets, are both G-protein coupled receptors. 62, 63 Because the ADP receptors P2Y 1 and P2Y 12 are also G-protein coupled receptors, the existence of similar intracellular signaling pathways are most likely. The presumed common intracellular signaling cascades, therefore, bear the option for interaction between thrombin-induced and ADP-induced platelet activation. Of note, thrombin receptor-mediated signaling seems to be dependent on the release of secreted ADP, 62 and P2Y 12 -inhibition by clopidogrel, blocking ADP-triggered platelet activation, has been shown to effectively reduce platelet-facilitated thrombin generation.
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Potential Mechanisms of Increased Incidence of Stroke Related to TA
Specifically looking at stroke, it first has to be pointed out that the reported actual number of incidents was actually relatively small. More recently, Brown et al 65 already reported on potential mechanisms of how stroke may be caused by TA during PPCI: first, a thrombus that cannot be fully aspirated is at risk of fracturing and shedding fragments into the systemic vasculature, particularly if fragments are sheared off because it Figure 1 . Factors related to platelet activation, thrombin generation, and conversion of fibrinogen to fibrin. Tissue factor (TF)-expressing cells activate small amounts of factor X to Xa on the cell surface resulting in thrombin generation. Factor Xa is only active on the cell surface where it is protected from its inactivation through TF pathway inhibitor and antithrombin. Thereafter, thrombin (factor IIa) unfolds its various effects, including platelet activation, through PAR (protease-activated receptor) 1 and 4 and coagulation resulting in the formation of fibrin from fibrinogen. Thrombin-induced platelet activation results in degranulation and ADP release, which in turn activates platelet ADP receptors, such as P2Y 12 . On the platelet surface, factor X is activated as well, again resulting in thrombin generation and finally conversion of fibrinogen to fibrin. Thrombus Aspiration for STEMI is withdrawn into the guide catheter. Second, a thrombus that cannot be fully aspirated through the TA catheter is at risk of exiting the catheter intact and entering the systemic vasculature, especially if suction is not maintained on the TA catheter as it is withdrawn. In both cases, the risk may be particularly increased if the guide catheter is not engaged in the coronary artery when the TA catheter is withdrawn. But there are also additional factors one might think of that can easily contribute to a higher risk of stroke, such as the general need for sheaths and catheters >5F, additional procedural catheter changes, and generally longer procedure times. One might even speculate that medical treatment might not necessarily have been identical in TA as compared with PCI alone because of further considerations of the interventionist in charge.
Particularly in the light that several prior-mostly smaller and shorter-studies did not report a significant increase in stroke rates, the hypothesis has to be taken thoroughly into account that a large portion of strokes may in fact not have been related directly to the TA procedure in terms of thrombus dislodgement but was actually caused by additional factors. This viewpoint is also strengthened by the findings from the most recent trials, showing that many of the strokes occurred >30 days after angioplasty. These late-onset strokes might hint that stroke occurrence might either relate largely to TA-independent factors, such as medication during and after the procedure, or can most probably at least in large part be attributed to currently unknown pathomechanisms, such as acceleration of pathological systemic processes by TA. In this context, 1 relevant mechanism might be a systemic response to ischemic injury aggravating chronic atherosclerosis. Recently, Dutta et al 66 have shown that apoE −/− mice developed larger atherosclerotic lesions with a more advanced morphology past MI, with disease acceleration persisting for many weeks associated with markedly increased monocyte recruitment. It can be hypothesized that similar currently still largely unknown activating pathomechanisms might be triggered and, therefore, play a key role in the development of late-onset stroke after TA in PPCI.
Future Perspective
The future of TA currently remains uncertain because of the many controversial facts discussed above. An updated general algorithm suggested to improve TA use during emergency PCI in patients with STEMI in a real-world clinical setting based on current basic and clinical knowledge is given in Figure 2 . Future perspective of TA might be affected largely by the following aspects:
a. Future clinical trials: the narrative of manual TA reinforces the enduring necessity for additional large, randomized clinical trials that are inclusion and exclusion criteria strict, standardize TA-operating procedures, and provide longer-term follow-up to determine whether velopment of a more concise, more efficient, and more secure TA device. f. Answers from basic research? Related basic research focusing on the reperfusion injury, post-TA microvascular perfusion, and systemic inflammatory response might encourage the clinical use of TA or not. In conclusion, despite controversial trial data on the efficacy of manual TA during PPCI, especially the lack of clinical benefit associated with its routine use in STEMI, the authors think that manual TA today still remains a useful tool of consideration for the interventional cardiologist in certain specific situations, especially when dealing with fresh thrombus and high thrombus burden. Based on current knowledge, in cases where TA is considered, use of glycoprotein IIb/IIIa inhibitors during the procedure should be regarded standard of care.
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